不同分子分型乳腺癌Ki67、P53的表达及临床病理特点研究

Study on Ki67 and P53 expression and clinicopathological characteristics in different molecular subtypes of breast cancer

目的研究不同分子分型乳腺癌Ki67抗原、P53的表达及临床病理特点。方法选取2016年1月至2019年12月重庆医科大学附属第二医院收治的给予手术治疗的原发性乳腺癌患者502例作为研究对象并收集其临床资料,观察不同分子分型乳腺癌Ki67、P53的表达及临床病理特点。结果502例患者中Lumina A型136例(27.09%),Luminal B型218例(43.43%),Her-2过表达型65例(12.95%),Basal-like型83例(16.53%)。不同分子分型患者年龄分布、乳腺癌Ki67表达量、肿瘤直径、病理分级、腋窝淋巴结转移数比较,差异均有统计学意义(P<0.05);不同分子分型乳腺癌P53表达量比较,差异无统计学意义(P>0.05)。结论Ki67及临床病理特点可在预测患者预后及制定治疗方案方面提供指导意义。

Objective To study the Ki67 antigen and P53 expression and clinicopathological characteristics in different molecular types of breast cancer.Methods A total of 502 patients with primary breast cancer treated by surgery in the Second Affiliated Hospital of Chongqing Medical University from January 2016 to December 2019 were selected as the research subjects and their clinical data were collected to observe the Ki67 and P53 expressions and clinicopathological characteristics in different molecular types of breast cancer.Results Among 502 cases,136 cases were the Luminal A type,accounting for 27.09%,218 cases were the Luminal B type,accounting for 43.43%,65 cases were the Her-2 overexpression type,accounting for 12.95%and 83 cases were the Basal-like type,accounting for 16.53%.The Ki67 expression level,age distribution,tumor diameter,number of axillary lymph node metastasis and pathological grade had statistical differences among the patients with different molecular types(P<0.05).There was no statistically significant difference in the P53 expression level among different molecular types(P>0.05).Conclusion Ki67 and clinicopathological features can provide the guidance significance for predicting the patient′s prognosis and formulating the treatment scheme.